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Abstract Facioscapulohumeral muscular dystrophy (FSHD) involves sporadic expression of
DUX4, which inhibits myogenesis and is pro-apoptotic. To identify target genes, we over-expressed
DUX4 in myoblasts and found that the receptor tyrosine kinase Ret was significantly up-regulated,
suggesting a role in FSHD. RET is dynamically expressed during myogenic progression in mouse
and human myoblasts. Constitutive expression of either RET9 or RET51 increased myoblast
proliferation, whereas siRNA-mediated knockdown of Ret induced myogenic differentiation.
Suppressing RET activity using Sunitinib, a clinically-approved tyrosine kinase inhibitor, rescued
differentiation in both DUX4-expressing murine myoblasts and in FSHD patient-derived myoblasts.
Importantly, Sunitinib also increased engraftment and differentiation of FSHD myoblasts in
regenerating mouse muscle. Thus, DUX4-mediated activation of Ret prevents myogenic
differentiation and could contribute to FSHD pathology by preventing satellite cell-mediated
repair. Rescue of DUX4-induced pathology by Sunitinib highlights the therapeutic potential of
tyrosine kinase inhibitors for treatment of FSHD.
DOI: 10.7554/eLife.11405.001
Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is a prevalent myopathy, affecting 12/100,000 peo-
ple (Deenen et al., 2014). Although clinical severity is highly variable, skeletal muscle weakness
often appears first in the facial and shoulder girdle muscles, with muscles of the trunk and lower
extremities becoming affected as the disease progresses. Distinctive features of FSHD include asym-
metric skeletal muscle wasting and scapular winging (Tawil, 2008). Analysis of myoblasts from FSHD
patients has revealed direct functional impairments, including increased susceptibility to oxidative
stress (Winokur et al., 2003a, 2003b; Celegato et al., 2006; Macaione et al., 2007; Barro et al.,
2010), up-regulation of apoptotic markers (Winokur et al., 2003a, 2003b; Sandri et al., 2001;
Vanderplanck et al., 2011; Laoudj-Chenivesse et al., 2005) and repression of MYOD and MYOD-
target genes (Winokur et al., 2003b; Celegato et al., 2006). Additionally, myogenic differentiation
results in myotubes with either an atrophic, or hypertrophic and highly disorganised morphology
(Barro et al., 2010; Vanderplanck et al., 2011; Tassin et al., 2012; Ansseau et al., 2009). Defects
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in myoblast function are likely to result in impaired muscle maintenance, directly contributing to clini-
cal symptoms (Morgan and Zammit, 2010).
FSHD is divided into two clinically indistinguishable disorders. FSHD1 (1A) (OMIM #158900) is
associated with the contraction of a macrosatellite repeat named D4Z4 in the subtelomeric region
4q35 (Tawil, 2008; van Deutekom et al., 1993). Embedded within each 3.3 kb D4Z4 repeat unit is
an open reading frame (ORF) for Double homeodomain protein 4 (DUX4), an intron-less retrogene
(Dixit et al., 2007; Gabrie¨ls et al., 1999). Contraction of D4Z4 units to between 1–10 is associated
with de-repression of chromatin (van Deutekom et al., 1993; Zeng et al., 2009; de Greef et al.,
2009). If this occurs on a permissive chromosomal 4qA haplotype containing a polyadenylation site
within the flanking pLAM region, DUX4 mRNA transcript from the distal D4Z4 repeat is stabilised
and DUX4 protein translated (Dixit et al., 2007; Lemmers et al., 2010; Snider et al., 2010). In the
rarer FSHD2 (1B) (OMIM #158901), de-repression of the D4Z4 macrosatellite occurs despite the
presence of >11 D4Z4 repeats, but still requires the permissive 4qA haplotype containing the polya-
denylation signal (de Greef et al., 2009, 2010). FSHD2 has recently been linked to mutations in the
Structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1) gene, encod-
ing a protein involved in DNA methylation (Lemmers et al., 2012). Recently, mutations in DNA
methyltransferase 3B (DNMT3B) have also been implicated in perturbed epigenetic regulation in
FSHD (van den Boogaard et al., 2016). Taken together, the consensus is that aberrant DUX4
expression underlies pathogenesis in both FSHD1 and FSHD2 (Tawil et al., 2014).
Two main DUX4 mRNA transcripts can be derived from the ORF in a D4Z4 repeat: DUX4-fl (full
length) mainly expressed in germline cells, and the alternatively spliced DUX4-s (short) transcript
expressed in some somatic cells. FSHD skeletal muscle expresses DUX4-fl whereas this transcript is
not usually found in healthy control muscle (Snider et al., 2010), although very low levels have been
reported in some studies (Jones et al., 2012; Tassin et al., 2013). Expression of DUX4 in myoblasts
recapitulates the pathogenic phenotype of myoblasts from FSHD patients (Vanderplanck et al.,
2011; Yao et al., 2014; Mitsuhashi et al., 2013; Bosnakovski et al., 2008a; Knopp, 2011;
Geng et al., 2012; Bosnakovski et al., 2014; Kowaljow et al., 2007; Wallace et al., 2011;
Geng et al., 2011; Banerji et al., 2015). Indeed, suppression of DUX4 expression using siRNA or
anti-sense oligonucleotides rescues the atrophic phenotype of FSHD myotubes in vitro
(Vanderplanck et al., 2011). DUX4 is a potent transcription factor and analysis of DUX4-expressing
myoblasts has revealed that major transcriptional pathways such as cell cycle regulation, glutathione
redox metabolism, myogenic differentiation and Wnt signalling are disrupted (Bosnakovski et al.,
2008a; Geng et al., 2012; Banerji et al., 2015). In addition, many germline and neural genes are
upregulated (Banerji et al., 2015; Dandapat et al., 2013). However, DUX4 is at very low levels in
FSHD biopsies (Tassin et al., 2013). Despite this, we, and others, have shown that the transcriptional
landscape of genes altered by DUX4 is much more prominent in FSHD patient-derived material
(Yao et al., 2014; Banerji et al., 2015). Therefore, identification of DUX4-induced pathways that
contribute to pathology in FSHD and are targetable with drugs provides a useful route for potential
FSHD-specific therapies. We have focussed on the effects of DUX4 on myoblasts, to identify
approaches to improve muscle repair and regeneration.
At present, there is no single mammalian animal model that encompasses the genetic and patho-
physiological spectrum of FSHD (Lek et al., 2015). To model FSHD, we have used retroviral-medi-
ated expression of DUX4, in conjunction with constitutively active and dominant-negative versions,
in primary murine satellite cells cultured ex vivo. Comparing gene expression data from DUX4-
expressing murine satellite cell-derived myoblasts to a meta-analysis of published microarrays from
FSHD patient biopsies and primary cultures (Banerji et al., 2015), we revealed a significant overlap
between DUX4-expressing murine satellite cell-derived myoblasts and human FSHD muscle
(Knopp et al., 2016).
We found that the receptor tyrosine kinase (RTK) Rearranged during transfection (RET) is up-regu-
lated in DUX4-expressing myoblasts (Banerji et al., 2015; Dandapat et al., 2013). RET is a trans-
membrane RTK containing 4 cadherin-like repeats, a cysteine-rich area, a calcium-binding site on the
extracellular region and several intracellular tyrosine kinase domains (Santoro et al., 2004;
Airaksinen and Saarma, 2002). There are two main RET isoforms; RET9 and RET51, alternatively
spliced in the 3’ region, resulting in an additional tyrosine at Y1096 on RET51 (Jain et al., 2006).
These two main RET isoforms are differentially expressed, regulated and have diverse roles in
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development and tissue homeostasis (Yoong et al., 2005; Tsui-Pierchala et al., 2002;
Richardson et al., 2012; Jain et al., 2010).
RET is activated by the secreted Glial cell-derived neurotrophic factor (GDNF) family ligands
(GFL): GDNF, neurturin (NRTN), artemin (ARTN) and persephin (PSPN). GFLs bind with high affinity
to one of four glycosylphosphatidylinositol (GPI)-anchored co-receptors of the GDNF Family Recep-
tor (GFRa) family. GFL:GFRa complexes then recruit two RET molecules, triggering RET dimerisation
and trans-phosphorylation of the intracellular region of both molecules. This leads to recruitment of
adaptor proteins and activation of downstream signalling cascades such as MAPK, PI3/AKT, JAK/
STAT, JNK, ERK5, SRC and PLCg (Santoro et al., 2004; Airaksinen and Saarma, 2002; Runeberg-
Roos and Saarma, 2007; Mulligan, 2014). RET9 and RET51 activate PI3K/AKT and ERK signalling
with different dynamics and have distinct abilities to recruit Src or Frs2, suggesting differential acti-
vation of downstream targets by the two main RET isoforms (Tsui-Pierchala et al., 2002;
Ishiguro et al., 1999; Besset et al., 2000).
Coordinated RET signalling is crucial for development of multiple tissues, including many neuro-
nal cell types, kidneys and the thyroid gland (Runeberg-Roos and Saarma, 2007; Arighi et al.,
2005). Indeed, RET knockout mice can be embryonic lethal with a wide range of organ defects
(Jain et al., 2010; Schuchardt et al., 1994; de Graaff et al., 2001). RET signalling has also been
shown to regulate spermatogonial and haematopoietic stem cell function (Naughton et al., 2006;
Fonseca-Pereira et al., 2014). Dysregulated RET signalling is associated with disease: inactivating
mutations of RET lead to a form of neurocristopathy called Hirschsprung’s disease (Amiel et al.,
2008), whereas mutations of RET resulting in constitutively active isoforms are associated with sev-
eral forms of inherited and somatic cancers (Arighi et al., 2005; Borrello et al., 2013). For example,
mutations at codon 634 of RET are found in approximately 84% of multiple endocrine neoplasia
(MEN2A) patients (Santoro et al., 2004; de Graaff et al., 2001; Mulligan et al., 1993).
Studies detailing expression of Ret, the GFL’s and GFRa’s in developing or adult rat, mouse and
human skeletal muscle report expression of at least some RET signalling components, predominantly
during development e.g. (Worby et al., 1998; Naveilhan et al., 1998; Russell et al., 2000;
Lindahl et al., 2001; Yang et al., 2006; Mikaels et al., 2000; Golden et al., 1999; Yang and Nel-
son, 2004). Interestingly, Ret and Gdnf mRNA transcripts have been shown in mesenchymal cells of
the second branchial arch in E9-9.5 mouse embryos (Golden et al., 1999; Natarajan et al., 2002),
from which some facial muscles develop. We recently reported that ret is important for skeletal mus-
cle development in zebrafish, where ret-gfra3-artemin signalling is required to regulate myogenic
differentiation in a subset of muscle precursors deriving from the first and second brachial arches
(Knight et al., 2011).
Here we show that Ret is a novel mediator of satellite cell function, contributing to the regulation
of proliferation and initiation of myogenic differentiation. Critically, DUX4-mediated Ret signalling is
pathogenic to satellite cells, contributing to impaired differentiation. However, blocking DUX4-medi-
ated Ret signalling using siRNA or the RTK inhibitor Sunitinib, leads to an increase in the myogenic
capacity of DUX4-expressing murine satellite cells. Importantly, Sunitinib also improves proliferation
and differentiation in FSHD patient-derived myoblasts both in vitro, and in vivo after grafting into
regenerating muscle in mice. These observations highlight using RTK inhibitors as a potential thera-
peutic strategy for FSHD.
Results
Ret and Ret co-receptors are expressed in murine myoblasts
To determine whether Ret is expressed in murine satellite cells, myofibres with their associated satel-
lite cells were isolated and either fixed immediately (T0), or cultured for 24 (T24) or 72 (T72) hours.
Co-immunolabelling to detect Pax7 and Ret51 of fixed myofibres at T0 and T24 revealed that Ret51
was barely detectable in quiescent satellite cells, but expression increased after 24 hr of activation
(Figure 1A and B). This correlated with an increase in phospho-Ret Tyr1062 immunolabelling, indica-
tive of active Ret signalling. By T72, a proportion of satellite cell-derived myoblasts stop expressing
Pax7 and commit to myogenic differentiation, expressing Myogenin (Zammit et al., 2004). Ret51
was found in both Myogenin-negative uncommitted myoblasts and Myogenin-positive differentiating
myoblasts (Figure 1C).
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Figure 1. Expression dynamics of Ret and Gfra co-receptors during myogenic progression in murine satellite cell-
derived myoblasts. Co-immunolabelling of Ret in satellite cells associated with isolated myofibres. (A–C)
Expression of Ret51 and phosphorylated (Y1062) Ret (pRet) in quiescent (T0) Pax7-positive satellite cells (A), Pax7-
positive satellite cells cultured for 24 hr (T24) (B) and expression of Ret51 in differentiation-committed Myogenin-
positive and Myogenin-negative satellite cells (C). DAPI (blue) was used as a nuclear counterstain. (D–G) Relative
expression dynamics of Ret and its co-receptors Gfra1, Gfra2 and Gfra4 during satellite cell proliferation (prolif.)
and through differentiation (DM 6–48 hr), normalised to Tbp. Data is mean ± SEM from 3 independent
experiments using 3 mice. An asterisk denotes significant difference (p<0.05) from the expression level in
proliferating cells, as determined using a paired Student’s t-test. Scale bar equals 50 mm.
DOI: 10.7554/eLife.11405.002
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Next, the expression of Ret and its Gfra co-receptors was profiled during myogenic progression.
Satellite cell-derived myoblasts were isolated from three 8-week old C57BL/10 mice and mRNA har-
vested from plated expanded cultures in proliferation medium or after 6, 12, 24 or 48 hr in differen-
tiation medium (Figure 1D–G). Ret, Gfra1, Gfra2 and Gfra4, but not Gfra3, were robustly expressed
in these myoblast cultures. Expression of Ret decreased during myoblast differentiation, whereas
Gfra1, Gfra2 and Gfra4 increased upon differentiation.
RET is expressed in human myoblasts
We next investigated expression of RET in human primary satellite cell-derived myoblasts (Figure 2).
Primary myoblasts were isolated from vastus lateralis of three 19-year old females and the CD56+
fraction purified using magnetic-activated cell sorting (Agley et al., 2015). CD56+ satellite cell-
derived myoblasts from each individual were cultured in proliferation medium or in differentiation
medium for 1, 2, 3 or 4 days. Cultures were fixed and immunolabelled to confirm differentiation
(Figure 2A). RNA was extracted from sister cultures for RT-qPCR analysis, which revealed that RET
was detectable at low levels in proliferating and differentiating human primary myoblasts
(Figure 2B), with control genes CYCLIN D1, MYOD, MYOG and MYHC used to confirm prolifera-
tion/differentiation status (Figure 2C–F).
Ret is required for satellite cell proliferation
To test whether satellite cells require Ret for normal function, we performed siRNA-mediated knock-
down. Expanded murine satellite cell cultures were transfected with 20 nM of Ret siRNA directed at
both Ret9 and Ret51 isoforms, or a scrambled-sequence control siRNA, for 48 hr. Knockdown was
assessed by RT-qPCR, with a mean knockdown efficiency of ~80% achieved. siRNA-treated satellite
cell-derived myoblasts were pulsed for two hours with the thymidine analogue 5-Ethynyl-2’-deoxyuri-
dine (EdU), which incorporates into DNA during S phase of the cell cycle and can be used to mea-
sure relative proliferation rate, and then immunolabelled for Pax7 (Figure 3A). Knockdown of Ret
significantly reduced the proportion of myoblasts that had incorporated EdU, from a mean ± SEM of
44.0 ± 4.5% to 28.0 ± 3.2% (Figure 3B). Sister cultures of siRNA-treated myoblasts were then co-
immunostained with phosphorylated-histone H1 and phosphorylated-histone H3 protein to identify
specific stages of the cell cycle (Lu et al., 1994; Knopp et al., 2013; Hendzel et al., 1997). This con-
firmed that Ret knockdown led to decreased proliferation, with significantly fewer cells in S and G1
phases (Figure 3C).
SiRNA-mediated knockdown of Ret was also associated with a small decrease in the proportion
of myoblasts containing Pax7 protein (Figure 3D). The reduced number of proliferating, Pax7
expressing myoblasts when Ret is knocked down suggests that Ret contributes to maintaining myo-
blasts in an undifferentiated state. We also observed a reduction of Pax7 expression in response to
Ret knockdown (Figure 3E). Although Pax7 is genetically upstream of MyoD and Myf5 (Relaix et al.,
2005), Ret knockdown did not alter MyoD (Figure 3F) or Myf5 expression (Figure 3G).
Knockdown of Ret enhances myogenic differentiation of satellite cell-
derived myoblasts
Satellite cell-derived myoblasts treated with Ret siRNA had reduced Pax7 expression and prolifera-
tion rate, implying that they may be differentiating prematurely. To investigate this, cultures were
treated with control or Ret siRNA, plated at high density and incubated in differentiation medium
for 48 hr, before immunolabelling for Myogenin and Myosin Heavy Chain (MyHC) (Figure 3H and I).
The proportion of Myogenin-positive nuclei was significantly increased in Ret siRNA-treated cultures
relative to control siRNA-treated cells (85.4 ± 4.0% versus 69.1 ± 4.0%) (Figure 3J). In contrast, the
proportion of nuclei in MyHC-expressing multinucleate myotubes (presented as the fusion index: the
proportion of nuclei in myotubes of 2 or more nuclei, Figure 3K) was unaltered in control cells (60.0
± 3.0%) compared to cells treated with Ret siRNA (62.7 ± 2.2%). To determine if the extent of myo-
blast fusion was affected, myotubes were classified by the number of nuclei per myotube (small
(2>4), medium (5>9), large (10>24) and extra-large (25+). Ret siRNA knockdown led to more large
myotubes (10.7 ± 1.9%) relative to control (5.4 ± 1.8%, Figure 3L).
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Figure 2. RET is expressed in proliferating and differentiating primary human satellite cell-derived myoblasts. (A) Immunolabelling of primary human
myoblasts extracted from the vastus lateralis of 3 individuals (Exp. 1 to 3) co-immunolabelled for Desmin (red – cytoplasmic), Ki67 (mauve – nuclear),
Myogenin (green – nuclear), MyHC (grey – cytoplasmic) and counterstained with DAPI (blue – nuclear). (B–F) Relative expression of (B) RET, (C) Cyclin
D1, (D) MYOD, (E) MYOG and (F) MYHC transcription during proliferation (Prolif.) and after 1, 2, 3 and 4 days in differentiation medium (DM1-4),
measured by RT-qPCR and normalised to RPLPO housekeeping gene. Data is mean ± SEM where an asterisk denotes significant difference (p<0.05)
from the expression level in proliferating cells, as determined using a paired Student’s t-test. Scale bar equals 50 mm.
DOI: 10.7554/eLife.11405.003
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Figure 3. Knockdown of Ret enhances myogenic differentiation of satellite cells. (A) Satellite cell-derived myoblasts transfected with control or Ret
siRNA for 48 hr and pulsed for 2 hr with EdU (red) to measure the proliferation rate, and immunolabelled for Pax7 (green) and counterstained with DAPI
(blue), quantified in (B and D). (C) Quantification of satellite cell-derived myoblasts transfected with control or Ret siRNA and labelled with phospho-
Histone H1/H3. Cells were grouped according to their cell cycle stage. (E–G) RT-qPCR analysis of the relative expression of Pax7, MyoD and Myf5 in
Figure 3 continued on next page
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Knockdown of Gfra2 or Gfra4 recapitulates aspects of Ret knockdown
To determine which Gfra co-receptors expressed in satellite cell-derived myoblasts may activate Ret
signalling, myoblasts were transfected with siRNA against Gfra1, Gfra2, Gfra4, or scrambled control
siRNA, for 48 hr, before cells were immunolabelled for phospho-Histone H1/H3, Pax7, Myogenin
and MyHC (Figure 4A–D). Phospho-Histone H1 and H3 immunostaining revealed that knockdown of
Gfra1, Gfra2 and Gfra4 were associated with fewer cells in the active stages of the cell cycle
(Figure 4A). As with Ret siRNA, knockdown of Gfra4 (but not Gfra1 or Gfra2) was associated with
Figure 3 continued
satellite cell-derived myoblasts transfected with control or Ret siRNA for 48 hr, with expression normalised to Gapdh. (H and I) Satellite cell-derived
myoblasts transfected with Ret or control siRNA and incubated in differentiation medium for 48 hr, immunolabelled with Myogenin (red) and
counterstained with DAPI (blue) (H) or Myosin Heavy Chain (MyHC - green) and counterstained with DAPI (blue) (I), quantified in (J–L). (L) Quantification
of the relative proportion of small (2 > 4 nuclei), medium (5 > 9 nuclei), large (10 > 24 nuclei) and very large (25+ nuclei) myotubes. Data is mean ± SEM
from 3–4 mice in each case, where statistical difference (p<0.05) from control siRNA was determined using a paired Student’s t-test and denoted by an
asterisk. Scale bars equal 50 mm (A) and 200 mm (H and I).
DOI: 10.7554/eLife.11405.004
Figure 4. Gfra1, Gfra2 and Gfra4 affect myoblast proliferation and myogenic differentiation. (A–D) Quantification
of satellite cell-derived myoblasts transfected with control or Gfra1, Gfra2 or Gfra4 siRNA for 48 hr in proliferation
medium (A and B) or differentiation medium (C and D). Immunolabelling of cells was performed to quantify the
proportion in the cell cycle using anti-phospho-Histone H1 and H3 (A), the proportion containing immunosignal
for Pax7 (B), Myogenin (C) and the proportion of nuclei in multinucleated myotubes (fusion index) (D). Data is
mean ± SEM from 3 independent experiments using 3 mice, where statistical difference (p<0.05) from control
siRNA was assessed using a paired Student’s t-test and denoted by an asterisk.
DOI: 10.7554/eLife.11405.005
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fewer Pax7-containing satellite cell-derived myoblasts in proliferation medium, from 82.8 ± 2.0% in
controls to 69.8 ± 4.3% in cells with siRNA to Gfra4 (Figure 4B). After 48 hr in differentiation
medium, the proportion of Myogenin-positive nuclei was significantly increased following knock-
down of Gfra2 and Gfra4 (Figure 4C). Additionally, knockdown of Gfra4 significantly increased the
fusion index (from 39.3 ± 3.1% in the control sample to 46.8 ± 3.0% with Gfra4 siRNA (Figure 4D).
Taken together, knockdown of Gfra co-receptors recapitulated aspects of Ret knockdown, indicat-
ing that multiple co-receptors may signal through Ret in muscle stem cells.
Active Ret signalling drives myoblast proliferation but does not affect
differentiation
We next used retroviral-mediated constitutive expression to examine the effects of increased RET
expression on satellite cell proliferation and differentiation. Human RET9 and RET51, together with
constitutively active (CA) RET9 and CA RET51 (containing a Cys634Lys mutation causing ligand-inde-
pendent dimerisation of the RET receptor [Mulligan et al., 1993]), were cloned into a retroviral
backbone containing an IRES-eGFP to identify transduced cells. These retroviral constructs encoded
RET protein of 170kDa as expected (Figure 5A) and human RET mRNA was present 48 hr after
transduction of mouse myoblasts (Figure 5B). Expression of endogenous murine Ret was unaltered
by human RET expression (Figure 5C).
To ascertain whether RET affects proliferation rate, myoblasts were infected with retroviruses
encoding the RET isoforms and pulsed with EdU for 2 hr in proliferation medium. Constitutive
expression of either wild-type RET9 or RET51 did not alter the proportion of eGFP+/EdU+ myo-
blasts compared to transduction with control retrovirus. However, the CA RET constructs signifi-
cantly increased proliferation rate, with EdU incorporation rising from 47.6 ± 0.8% in controls to 56.9
± 1.8% (CA RET9) and 59.2 ± 1.7% (CA RET51) (Figure 5D and E). RET did not alter the overall pro-
portion of Pax7-containing cells (Figure 5F and G).
To determine whether constitutive expression of RET affects myogenic differentiation, we ana-
lysed expression of Myogenin and MyHC in myoblasts cultured in differentiation medium
(Figure 5H–K). After 24 hr of differentiation, CA RET51 reduced the proportion of myoblasts that
contained Myogenin (49.5 ± 1.2%) relative to controls (58.9 ± 3.1%), but by 48 hr there was no lon-
ger any difference (Figure 5H and I). At this stage, there was no alteration in fusion index (Figure 5J
and K).
DUX4 induces Ret in satellite cell-derived myoblasts
To identify genes affected by DUX4 expression, we analysed our microarray data (GSE77100, http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77100), which measured transcriptional changes
in murine satellite cell-derived myoblasts 20 hr after transduction with retroviruses encoding DUX4,
DUX4c (a truncated homologue of DUX4 containing the same homeodomains, encoded by a D4Z4
unit centromeric to the macrosatellite [Bosnakovski et al., 2008b]), truncated (tMALDUX4), constitu-
tively active (tMALDUX4-VP16) or dominant-negative (tMALDUX4-ERD) DUX4 constructs
(Banerji et al., 2015). Ret expression was increased 3.45-fold in DUX4-expressing satellite cell-
derived myoblasts, and approximately 2 fold by either tMALDUX4-VP16 or tMALDUX4-ERD, relative
to controls. Expression of Ret co-receptors Gfra2, Gfra3 and Gfra4 were unaltered, although Gfra1
expression was reduced 0.57-fold by DUX4 (Figure 6A). Expression of DUX4c did not alter Ret or
Gfra co-receptor expression (Figure 6A).
To confirm that Ret is a downstream DUX4 target gene in satellite cell-derived myoblasts, we
transduced myoblasts with retroviral constructs encoding DUX4 or DUX4c. There was a trend for
DUX4 to increase Ret transcription after 24 hr (p=0.052), which increased significantly (97.5-fold)
after 48 hr, relative to control plasmid-transduced cells (Figure 6B). Using isoform-specific primers,
we found that DUX4 increased expression of Ret9 (150-fold) more than Ret51 (15.8-fold) after 48 hr
(Figure 6C and D). Using inducible iC2C12-DUX4 and iC2C12-DUX4c myoblasts (Dandapat et al.,
2013), expression of Ret was significantly increased after 12 hr of induction with 200ng/ml doxycy-
cline in the iC2C12-DUX4 line, compared to un-induced myoblasts, and maintained at elevated lev-
els at 24 and 48 hr of induction (Figure 6E). Induction of DUX4c in the iC2C12-DUX4c line did not
generally alter Ret expression (Figure 6F). DUX4 activation of Ret also led to the detection of
Moyle et al. eLife 2016;5:e11405. DOI: 10.7554/eLife.11405 9 of 35
Research article Cell Biology Human Biology and Medicine
membrane-located Ret protein, as revealed by immunolabelling with an antibody to Ret51 in DUX4-
infected myoblasts (Figure 6G).
Down-regulation of Ret rescues DUX4-mediated inhibition of myogenic
differentiation
Our findings that Ret is a DUX4 target that influences satellite cell proliferation and differentiation,
make it a good candidate to test inhibitors for ameliorating DUX4-induced pathogenesis. A major
Figure 5. Active RET signalling drives satellite cell-derived myoblast proliferation. (A) Immunoblot analysis of the RET protein in HEK 293T cells
transfected with plasmids encoding human RET 9, RET 51, CA RET9 and CA RET51 for 24 hr. Equal quantities of total protein extracts were run on 4–
20% gradient PAGE-SDS gels, transferred and blotted with antibodies recognising both RET isoforms (pan-RET, top band and RET51, middle band).
Bands of 170 kDa were detected in HEK 293T cells transfected with RET-encoding plasmids, but not in cells transfected with control plasmid. b-Tubulin
was used as a loading control. (B–K) Satellite cell-derived myoblasts transduced with control retrovirus encoding eGFP alone, or retroviruses encoding
RET 9, RET 51, CA RET9 or CA RET51, together with GFP. mRNA was prepared (B–C) or myoblasts immunolabelled for eGFP (to identify transduced
cells) and assayed for EdU incorporation (D and E) or co-immunolabelled for eGFP and either Pax7 (F and G), Myogenin (H and I) or MyHC (J–K). (B–C)
RT-qPCR to measure expression of the human versions of RET (B) and endogenous murine Ret (C). (D and E) Quantification of the proportion of eGFP+
satellite cell-derived myoblasts incorporating EdU after a 2 hr exposure. (F–K) Quantification of the proportion of eGFP-expressing satellite cell-derived
myoblasts containing Pax7 (F and G), Myogenin (H and I) and the fusion index (J and K). RT-qPCR and quantification of immunolabelling is presented
as mean ± SEM from 3 or 4 independent experiments using 3–4 mice, where statistical difference (p<0.05) to transduction with control retrovirus was
assessed using a paired Student’s t-test and denoted by an asterisk. Scale bar equals 50 mm (D and F) or 200 mm (H and J).
DOI: 10.7554/eLife.11405.006
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Figure 6. DUX4 expression induces Ret in satellite cell-derived myoblasts. (A) Microarray data of expression levels
of Ret and Ret co-receptors Gfra1–4 in murine satellite cell-derived myoblasts transduced for 20 hr with
retroviruses encoding either DUX4, truncated DUX4 (tMALDUX4), constitutively active DUX4 (tMALDUX4-VP16),
dominant-negative DUX4 (tMALDUX4-ERD) or DUX4c (Banerji et al., 2015). Red highlights increased expression
while green highlights reduced expression (fold change) compared to transduction with control retrovirus. (B–D)
Quantification of total Ret, Ret9 and Ret51 expression by RT-qPCR in satellite cell-derived myoblasts transduced
with DUX4, DUX4c or control retroviruses at 24 and 48 hr post-infection. (E–F) Ret expression in iC2C12-DUX4
myoblasts (E) and iC2C12-DUX4c myoblasts (F) following 200ng/ml doxycycline (DOX) induction. (G) Satellite cell-
derived myoblasts transduced with DUX4-encoding retrovirus for 24 hr and immunolabelled for eGFP (green) to
identify transduced cells and anti-RET51 (red), with a DAPI counterstain (blue). Data is mean ± SEM from 3
independent experiments using 3 mice for (B–D) where statistical difference (p<0.05) from transduction with
control retrovirus was assessed using a paired Student’s t-test and denoted by an asterisk. For E and F , unpaired
Student’s t-tests were used to assess significance (p<0.05) compared to uninduced cells at each time point.
UI = un-induced, I = induced by doxycycline. Scale bar equals 100 mm (G).
DOI: 10.7554/eLife.11405.007
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feature of DUX4 expression in myoblasts is the induction of p53-dependent apoptosis
(Bosnakovski et al., 2008a; Kowaljow et al., 2007; Wallace et al., 2011; Wuebbles et al., 2010).
Interestingly, Ret is a dependence receptor, triggering apoptosis in the absence of its ligands
(Graf et al., 2007). Therefore, one might hypothesise that DUX4-mediated up-regulation of Ret in
the absence of sufficient GFLs could lead to cell death.
RT-qPCR revealed that both Ret isoforms were expressed in primary murine satellite cells
(Figure 7A). To test whether over-expression of RET isoforms can promote cell death, satellite cell-
derived myoblasts were transfected, rather than transduced, with RET plasmids, to induce high lev-
els of expression. Then the relative levels of active caspase 3/7 were measured in proliferating myo-
blasts using a luminescent assay. However, over-expression of either RET isoform significantly
reduced caspase 3/7 release, implying that DUX4-mediated up-regulation of RET does not contrib-
ute to the apoptotic phenotype (Figure 7B).
DUX4 also suppresses Pax7 and myogenic regulatory factor (MRF) gene expression and inhibits
proliferation and myogenic differentiation (Mitsuhashi et al., 2013; Bosnakovski et al., 2008a;
Knopp, 2011; Xu et al., 2014). To determine if we could rescue DUX4-induced pathology by inhibit-
ing Ret signalling, we measured the effects of siRNA-mediated inhibition of Ret in DUX4-expressing
murine satellite cell-derived myoblasts. Myoblasts transduced with control or DUX4 encoding retro-
virus were additionally transfected with 20 nM control or Ret siRNA for 48 hr in proliferation medium
and pulsed with EdU for two hours (Figure 7C). As expected, the proportion of transduced eGFP-
expressing myoblasts incorporating EdU was significantly reduced when either DUX4 was expressed
or when Ret was knocked down via siRNA transfection. Transfection of Ret siRNA into DUX4-
expressing cells did not significantly alter the proportion of cells incorporating EdU relative to con-
trol siRNA treated cells. Knockdown of Ret did not rescue the reduced number of eGFP+/Pax7+
myoblasts in the presence of DUX4 (Figure 7D). Together, this suggests that Ret knockdown is
unable to rescue the DUX4-mediated proliferation defect in murine primary myoblasts.
We then tested whether knockdown of Ret by siRNA could rescue myoblast differentiation in the
presence of DUX4 (Figure 7E). To assess significant rescue, to compensate for any biological vari-
ability and to identify interaction effects, we fitted the data to a binomial model. There was a slight
increase in the fusion index of myoblasts expressing control retrovirus and transfected with siRNA
against Ret relative to control siRNA (p=3.06  10–4, Figure 7E, F and G, Figure 7—source data 1).
Myoblasts expressing DUX4 (GFP+) had a dramatically reduced fusion index when transfected with
control siRNA (p=2.71  10–65). In contrast, Ret knockdown rescued myoblast fusion in the presence
of DUX4, relative to cells expressing DUX4 and transfected with a control siRNA (p=2.15  10–21).
Therefore, Ret knockdown significantly improves myogenic differentiation in the presence of DUX4.
Sunitinib, a clinically-approved kinase inhibitor, suppresses Ret
signalling to rescue myogenic differentiation
Next, we evaluated small molecule inhibitors of RET for their ability to affect myogenesis in the pres-
ence of DUX4. Three RTK inhibitors that block RET phosphorylation were tested: Zactima (Vandeta-
nib/ZD6474) (Carlomagno et al., 2002), TG101209 (Pardanani et al., 2007) and Sunitinib (Sutent,
SU11248) (Kim et al., 2006). Zactima and Sunitinib are both clinically approved as therapeutic
agents for treating cancers arising from over-activation of RET signalling (Durante et al., 2013;
Widmer et al., 2014).
Since Zactima, TG101209 and Sunitinib also inhibit several RTKs other than RET, including VEGFR,
EGF and MET (Plaza-Menacho et al., 2014), we first determined the dose needed to inhibit RET sig-
nalling and rescue differentiation in murine myoblasts. We tested different concentrations of each
drug on CA RET51-expressing murine C2C12 myoblasts, since we found that CA RET51 inhibits
myotube formation in this immortalised myoblast line. Thus, fusion in the presence of CA RET51
would indicate that the drug inhibits this constitutively-active human RET mutant. Statistical models
revealed that all inhibitors significantly rescued muscle differentiation in CA RET51-expressing
C2C12s (Figure 8A–C, Sunitinib: p=2  10–16, TG101209: p=2  10–16, Zactima: p=4.18  10–14,
Figure 8—source data 1). This occurred in a dose-dependent manner with Sunitinib, and to an
extent, with TG101209. Crucially, this dose-dependent response to Sunitinib and TG101209
occurred without overtly affecting cell number (Figure 8D–F, Figure 8—source data 2). Control
C2C12 myoblasts were unaffected by Sunitinib and TG101209 at low doses (up to 250 ng/ml), but at
higher doses, showed a small increase in fusion index. In contrast, Zactima significantly affected cell
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Figure 7. Knockdown of Ret rescues DUX4-mediated inhibition of myogenic differentiation. (A) Relative expression
of Ret9 and Ret51 in myoblasts infected with control retrovirus after 24 hr. (B) Quantification of a caspase 3/7 Glo
assay to measure apoptosis in satellite cell-derived myoblasts transfected with control plasmid encoding GFP, or
RET 9, RET 51, CA RET9 or CA RET51 encoding plasmids. (C–D) Quantification of proliferation by EdU
Figure 7 continued on next page
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number in a non-dose dependent manner and had a strong effect on fusion in control samples
(Figure 8C and F and Figure 8—source data 2). Sunitinib was selected for further analysis, as it pro-
moted an effective rescue of fusion in the presence of CA RET51, without causing large changes to
cell number (Figure 8G).
Sunitinib suppresses DUX4-mediated pERK1/2 signalling
To address the mechanism of Sunitinib in myoblasts, we examined characterised downstream targets
of Ret signalling, namely phosphorylated ERK1/2 (pERK1/2) and phosphorylated AKT (pAKT) e.g.
(Mograbi et al., 2001). DUX4 was induced in iC2C12-DUX4 myoblasts using 500 ng/ml doxycycline
with or without the addition of 250 ng/ml Sunitinib for 20 hr (Figure 8H). Western blot analysis
showed that Sunitinib significantly reduced pERK1/2 levels in DUX4-expressing myoblasts, without
affecting total ERK (Figure 8H and I). Total AKT and pAKT levels were unaltered by Sunitinib for
20 hr in iC2C12-DUX4 myoblasts expressing DUX4 (Figure 8H and J).
Sunitinib does not rescue proliferation or apoptosis in DUX4-expressing
murine myoblasts
We first assessed how 250 ng/ml Sunitinib affected proliferation in DUX4-expressing primary murine
satellite cells by measuring EdU incorporation (Figure 9A). There was no significant difference in
proliferation of control cells treated with DMSO vehicle control (43.5 ± 2.0%) or Sunitinib (43.3 ±
0.7%). Proliferation in DUX4-expressing myoblasts was also unaffected by Sunitinib (8.6 ± 2.0%) com-
pared to DUX4-expressing cells treated with DMSO (8.7 ± 1.7%, p<0.05) (Figure 9A and Figure 9—
source data 1).
DUX4 expression in myoblasts also leads to repression of MyoD (Bosnakovski et al., 2008a;
Snider et al., 2009). Treatment with Sunitinib rescued the number of MyoD-containing myoblasts in
the presence of DUX4 when analysed by a statistical model (p=3.8  10 4), although the relative
change was not large (Figure 9B and Figure 9—source data 2).
Additionally although expression of Ret in satellite cell-derived myoblasts was not apoptotic
(Figure 7B), it was important to understand whether Sunitinib affects apoptosis in DUX4-expressing
cells. iC2C12-DUX4 myoblasts were induced with 250 ng/ml and 500 ng/ml doxycycline for 24 hr,
which resulted in apoptosis (Figure 9C), and exposed to either 250 ng/ml or 500 ng/ml Sunitinib.
Live cells were stained with fluorescent-conjugated apoptotic markers Annexin V (AV) and propidium
iodide (PI), and analysed by flow cytometry (Figure 9C). While DUX4 expression increased the pro-
portion of iC2C12-DUX4 myoblasts gated as apoptotic (AV+/PI , AV /PI+ and AV+/PI+), treatment
with Sunitinib had no significant effect (Figure 9D).
Figure 7 continued
incorporation (C) and Pax7 expression (D) in eGFP-expressing myoblasts transduced with control or DUX4-
encoding retrovirus and then transfected with control or Ret siRNA for 48 hr. Data is mean ± SEM from 3 mice
where statistical difference (p<0.05) to control plasmid (B) or control retrovirus + control siRNA (C and D) was
assessed using a paired Student’s t-test and denoted by an asterisk. Bar is comparison between indicated
conditions, where N.S. denotes non-significant difference. (E) Immunolabelling of satellite cell-derived myoblasts
transduced with control or DUX4-encoding retrovirus and transfected with control or Ret siRNA following culture
for 24 hr in differentiation medium. Transduced cells were detected by immunolabelling for eGFP and examined
for MyHC to identify terminally differentiated myotubes. (F) The fusion index was calculated for eGFP-positive cells
expressing control or DUX4-encoding retrovirus and transfected with control or Ret siRNA. Bar represents
statistical test significance, where an asterisk denotes p<0.01. (G) Plot of probability that a cell has MyHC
immunoreactivity derived from binomial models (Figure 7—source data 1). Error bars represent 95% confidence
intervals. Four replicates were counted for each condition and repeated using 3 mice. Scale bar equals 200 mm (E).
DOI: 10.7554/eLife.11405.008
The following source data is available for figure 7:
Source data 1. Maximum likelihood parameters for a logistic model containing an interaction term, and a random
effect term describing the probability of a nucleus being present in a MyHC+ cell.
DOI: 10.7554/eLife.11405.009
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Figure 8. Sunitinib blocks the RET-induced phenotype in murine myoblasts. (A–C) Quantification of the fusion index of C2C12 myoblasts transduced
with control (red) or CA RET51-encoding retrovirus (blue) and treated with Sunitinib, TG101209 or Zactima at varying doses is shown as a statistical
model fitted to the –log of the odds ratio of the fusion index (-log ratio/(1-ratio)) (Figure 8—source data 1). (D–F) Quantification of the number of
C2C12 myoblasts transduced with control (red) or CA RET51-encoding retrovirus (blue) when treated with Sunitinib, TG101209 or Zactima at varying
doses (Figure 8—source data 2). (G) C2C12 myoblasts transduced with control or CA RET51-encoding retrovirus and induced to differentiate for 60 hr
in the presence of either 1 mg/ml Sunitinib or DMSO vehicle control, before co-immunolabelling with antibodies to eGFP (green) to detect transduced
cells and MyHC (red), with a DAPI nuclear counterstain (blue). All quantification represents an average of three independent experiments. Scale bar
equals 200 mm. (H) Representative immunoblot of proteins extracted from un-induced iC2C12-DUX4 myoblasts, or cells induced with 500ng/
ml doxycycline (Dox) to express DUX4, 250 ng/ml Sunitinib or both doxycycline and Sunitinib. Probed with antibodies against DUX4, total AKT,
phosphorylated (p) AKT, total ERK1/2 and phosphorylated (p) ERK1/2, with Caveolin-1 used as a loading control. All bands shown were visualised on
the same membrane. (I and J) Protein band intensity was quantified with the ChemiDoc MP System and normalised to housekeeping protein Caveolin-
1. The ratios of pERK1/2: total ERK1/2 and pAKT: total AKT in the treated groups were compared to the ratios in the control group. Quantification of
the ratio between pERK1/2: total ERK1/2 compared to control shows that Sunitinib suppresses DUX4-mediated pERK1/2 signalling. Data is mean ±
SEM from 3 independent experiments, where an asterisk denotes a significant difference (p<0.05) from Control using an unpaired Student’s t-Test.
DOI: 10.7554/eLife.11405.010
Figure 8 continued on next page
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Sunitinib rescues the myogenic capacity of DUX4-expressing murine
myoblasts
We next determined whether Sunitinib could rescue fusion in murine satellite cell-derived myoblasts
expressing DUX4. Myoblasts were cultured at high density in the presence of 125–500 ng/ml of Suni-
tinib and induced to differentiate for 24 hr prior to immunolabelling with MyHC (Figure 10A and B).
Fusion of control myoblasts was unaffected by Sunitinib at all doses (quantified in Figure 10C). Sta-
tistical models showed that the treatment of DUX4-expressing (GFP+) myoblasts with Sunitinib
increased fusion index at all doses, relative to cells treated with DMSO vehicle control (p<2  10 16,
Figure 10C, Figure 10—source data 1). This also revealed a saturation of the effect of Sunitinib at
concentrations above 250 ng/ml. Sunitinib treatment also increased the proportion of large myo-
tubes that formed in the presence of DUX4, and myotubes containing 25+ nuclei were only
observed in Sunitinib-treated samples.
To directly determine whether there is an interaction between Sunitinib and DUX4 in murine pri-
mary myoblasts that positively affects the fusion index, we next transduced myoblasts with control
or DUX4 retrovirus in the presence of DMSO or 250 ng/ml Sunitinib and induced them to differenti-
ate for 24 hr at high density (Figure 10D). We then used a logistic model to evaluate any interaction
(Figure 10E, Figure 10—source data 2). This revealed that the effect of Sunitinib on fusion is
dependent on the presence of DUX4 (p=2  10–16) and that there is a significant recovery of fusion
in the presence of DUX4 that is due to addition of Sunitinib (p=2.3  10–7).
Sunitinib enables DUX4-expressing murine myoblasts to differentiate
independently of fusion
Using a retroviral expression system to express DUX4 resulted in a transduction rate of approxi-
mately 40–50%. However, this approach does not allow determination of whether the increased rate
of fusion of DUX4-expressing cells in the presence of Sunitinib was due to Sunitinib rescuing the dif-
ferentiation defect directly, or by simply enabling DUX4-expressing myoblasts to fuse to control, un-
transduced myoblasts. To determine whether DUX4-expressing (GFP+) myoblasts could differentiate
independently of fusion, we seeded myoblasts at low density before treating with 250 ng/ml Suniti-
nib and inducing differentiation for 24 or 48 hr. Samples were then analysed on the basis of individ-
ual differentiated myocytes using immunolabelling to detect Myogenin and MyHC protein
(Figure 10F and G).
Sunitinib treatment on control-transduced samples did not change the proportion of myoblasts
expressing Myogenin (27.4 ± 1.1%), relative to controls (27.6 ± 0.9%) (p=0.86). In contrast, a signifi-
cant increase (p=0.028) was noted in the proportion of DUX4 expressing (GFP+) myocytes that were
Myogenin+ in the presence of Sunitinib (20.8 ± 1.9%) relative to untreated DUX4-expressing myo-
cytes (11.0 ± 0.6%). The proportion of GFP+ myoblasts expressing MyHC was significantly reduced
in the presence of DUX4 (2.4 ± 0.6%) relative to control cells (19.4 ± 2.5%, p=0.028) or to cells
exposed only to Sunitinib (21.1 ± 2.1%). In the presence of Sunitinib however, the proportion of
MyHC+ cells in DUX4-transduced cultures was significantly increased after 24 hr exposure (7.8 ±
1.3%) (p=0.016).
We then used statistical models to evaluate the importance of the interaction between Sunitinib
and DUX4 on Myogenin and MyHC expression in myocytes plated at low density (Figure 10F and
G). Sunitinib had no effect on the number of cells containing Myogenin after 24 or 48 hr in control
samples, in contrast to the marked reduction with DUX4 (p<2  10–16). The addition of Sunitinib sig-
nificantly rescued Myogenin expression in DUX4-expressing (GFP+) myoblasts at 24 (p<1.03  10–5)
Figure 8 continued
The following source data is available for figure 8:
Source data 1. Maximum likelihood parameters for a logistic model containing an interaction term and a random effect (mouse) to describe the effect
of CA RET51 (RET51-MENA) expression and Sunitinib, TG101209 or Zactima on fusion in C2C12 myoblasts.
DOI: 10.7554/eLife.11405.011
Source data 2. Quasi-Poisson model parameters for a fixed-effects factorial model incorporating a parameter to account for the replicate effects (Batch)
on the number of cells expressing CA RET51 (RET51-MEN2A) or control when treated with different concentrations of Sunitinib, TG101209 or Zactima.
DOI: 10.7554/eLife.11405.012
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and 48 hr (p<1.38  10–5, Figure 10F, Figure 10—source data 3). As with Myogenin, Sunitinib sig-
nificantly increased the proportion of DUX4-expressing (GFP+) cells with MyHC at 24 hr (p=4.21 
10–5) and 48 hr (p=7.94  10 3, Figure 10G, Figure 10—source data 4), thus Sunitinib improves
myogenic differentiation/fusion.
Figure 9. Sunitinib does not prevent apoptosis in DUX4-expressing myoblasts. (A–B) Quantification of murine
satellite cell-derived myoblasts transduced with control or DUX4-encoding retrovirus and treated with either 250
ng/ml Sunitinib (blue) or DMSO vehicle control (red). Cells were cultured at low density and incubated in
proliferation medium prior to immunolabelling to detect eGFP and either EdU (A) or MyoD (B). The ratio
represents the proportion of cells with EdU (A and Figure 9—source data 1) or MyoD (B and Figure 9—source
data 2) labelling in the presence (True, blue), or absence of Sunitinib (False, red). Bar represents statistical test
significance, where an asterisk denotes p<0.01 or N.S. means non-significant.(C) FACS analysis of murine iC2C12-
DUX4 myoblasts cultured in control medium (UI) or induced to express DUX4 with 250 ng/ml or 500 ng/ml
doxycycline and untreated (0), or exposed to 250 ng/ml or 500 ng/ml Sunitinib for 24 hr. (D) Quantification of the
mean proportion of apoptotic iC2C12-DUX4 myoblasts based upon the expression of Annexin V and propidium
iodide (PI). As a control, an asterisk denotes increased apoptosis by DOX-mediated induction of DUX4 compared
to un-induced cells (all without Sunitinib treatment). An average of 3 independent experiments, where statistical
difference to myoblasts not exposed to Sunitinib at each concentration of doxycycline was tested using an
unpaired two-tailed Student t-test, where p<0.05 represents significance (*).
DOI: 10.7554/eLife.11405.013
The following source data is available for figure 9:
Source data 1. Maximum likelihood parameters for a logistic model containing an interaction term, and a random
effect term (the mouse) that describes the proportion of myoblasts transduced with DUX4 or control retrovirus and
incorporating EdU when exposed to Sunitinib or DMSO.
DOI: 10.7554/eLife.11405.014
Source data 2. Maximum likelihood parameters for a logistic model containing an interaction term, and a random
effect term (the mouse) that describes the proportion of cells transduced with DUX4 or control retrovirus
and expressing MyoD when exposed to Sunitinib or DMSO.
DOI: 10.7554/eLife.11405.015
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Figure 10. Sunitinib rescues differentiation of DUX4-expressing myoblasts. (A) Satellite cell-derived myoblasts induced to differentiate in the presence
of varying doses of Sunitinib, and immunolabelled for MyHC (red) and counterstained with DAPI (blue). (B and C) Immunolabelling of satellite cell-
derived myoblasts transduced with retrovirus encoding DUX4 and GFP (green) to detect MyHC (red) following treatment with varying doses of Sunitinib
in differentiation medium. (C) Fusion index calculated as the ratio of nuclei in eGFP+/MyHC+ multinucleate cells/total nuclei (Figure 10—source data
Figure 10 continued on next page
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Sunitinib treatment improves proliferation and differentiation of FSHD
myoblasts
To determine whether Sunitinib improves myogenic differentiation in human FSHD myoblasts, we
obtained clonal cell lines derived from a mosaic FSHD1 individual (Krom et al., 2012): a control
clone containing a ‘healthy’ number of D4Z4 repeats (54.6) and a clone containing a pathogenic con-
traction of D4Z4 units and expressing DUX4 (54.12), thus apart from the number of DUX4 repeats,
both have the same genetic background. Although both clones proliferate and undergo differentia-
tion in culture (Krom et al., 2012), we found that the 54.12 pathogenic line proliferated at a slower
rate, had an eccentric cell shape and differentiated into smaller myotubes than the healthy 54.6 con-
trol myoblasts, as revealed by a lower fusion index (Figure 11). This phenotype is similar to that
reported for primary myoblasts from FSHD patients (Barro et al., 2010).
To determine if Sunitinib was able to rescue pathogenic phenotypes in the human FSHD cell line,
we treated both cell lines with varying concentrations of Sunitinib in either proliferation or differenti-
ation medium. There was no change in cell shape (eccentricity) of 54.6 control myoblasts in the pres-
ence of Sunitinib at any dose (Figure 11A and C). While 54.12 FSHD myoblasts treated with vehicle
control or the lower doses of Sunitinib (125 or 250 ng/ml) retained a significantly more elongated
cell shape relative to control 54.6 myoblasts (p<0.01), myoblasts treated with higher doses of Suniti-
nib no longer exhibited an abnormal cell shape compared to 54.6 controls (Figure 11C, Figure 11—
source data 1).
Importantly, the reduced proliferation rate of FSHD 54.12 myoblasts compared to 54.6 (p=2.55 
10–5) was rescued upon exposure to 250 ng/ml, 500 ng/ml or 750 ng/ml of Sunitinib, concentrations
which did not affect control 54.6 myoblasts (Figure 11A and D, Figure 11—source data 2).
Fusion of control 54.6 myoblasts was increased by Sunitinib at small, but significant, levels in a
non-linear manner. In contrast, Sunitinib had a strong and highly significant effect on the fusion index
of 54.12 cells at all concentrations tested (p<2  10–16). The fusion index increased in a dose-depen-
dent manner in the presence of 125 or 250 ng/ml of Sunitinib. 250 ng/ml Sunitinib had the most
potent effect on fusion of 54.12 myoblasts, achieving a level that was comparable to that of 54.6
myoblasts (Figure 11B and E). At doses of 500 or 750 ng/ml Sunitinib, a fusion of 54.12 myoblasts
was not enhanced to similar levels as observed at 250 ng/ml, suggestive of inhibitory effects at these
higher doses (Figure 11B and E, Figure 11—source data 3).
Thus, in myoblasts lacking the FSHD1-specific D4Z4 contraction, Sunitinib does not have a large
effect on human myoblast morphology, proliferation or ability to form multinucleated myotubes. In
Figure 10 continued
1). (D) Satellite cell-derived myoblasts transduced with control GFP or DUX4 and GFP-encoding retrovirus in the presence of 250 ng/ml Sunitinib or
DMSO at high density and induced to differentiate for 24 hr before co-immunolabelling with eGFP (green), MyHC (red) and counterstained with DAPI
(blue). (E) Fusion index quantified with myoblasts exposed to DMSO (False: red) or 250 ng/ ml Sunitinib (True: blue) (Figure 10—source data 2). (F and
G) Quantification of satellite cell-derived myoblasts transduced with control GFP or retrovirus encoding DUX4 and GFP and treated with either 250 ng/
ml Sunitinib (blue) or DMSO (red). Cultured at low density in differentiation medium for 24 or 48 hr (D1, D2) to form unfused myocytes and co-
immunolabelled with eGFP to identify transduced cells and either Myogenin (F and Figure 10—source data 3) or MyHC (G and Figure 10—source
data 4). All experiments were independently performed 3 times. The statistical significance of differences described in Figure 10—source data 1–
4. Bar represents statistical test significance, where an asterisk denotes p<0.01. Scale bar equals 200 mm.
DOI: 10.7554/eLife.11405.016
The following source data is available for figure 10:
Source data 1. Maximum likelihood parameters for a logistic model containing an interaction term between DUX4 and Sunitinib that describes the
fusion index of satellite-cells grown at high density with or without DUX4 transduction.
DOI: 10.7554/eLife.11405.017
Source data 2. Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) that
describes the fusion index of myoblasts transduced with DUX4 or control retrovirus and grown at high density when exposed to Sunitinib or DMSO.
DOI: 10.7554/eLife.11405.018
Source data 3. Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) to describe
MyoG expression in satellite cell-derived myoblasts expressing DUX4 or control retrovirus and exposed to Sunitinib or DMSO, when grown at low density.
DOI: 10.7554/eLife.11405.019
Source data 4. Maximum likelihood parameters for a logistic model containing an interaction term, and a random effect term (the mouse) to describe
MyHC expression in satellite cell-derived myoblasts expressing DUX4 or control retrovirus and exposed to Sunitinib or DMSO, when grown at low density.
DOI: 10.7554/eLife.11405.020
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Figure 11. Sunitinib improves the pathogenic phenotype of FSHD myoblasts. (A) Immunolabelling of mosaic FSHD patient-derived myoblast cell lines
54.6 (control) and 54.12 (FSHD) exposed to DMSO vehicle control or 500 ng/ml Sunitinib. EdU incorporation (red) was revealed using the Click-iT assay
and myoblasts immunolabelled for b-TUBULIN (green) with a DAPI nuclear counterstain (blue). (B) Immunolabelling of MYHC (red) in myoblasts grown
at high density in differentiation medium with either DMSO vehicle control or 500 ng/ml Sunitinib. (C–E) Quantification of cell shape (eccentricity)
assessed using b-TUBULIN immunolabelling (C and Figure 11—source data 1), EdU incorporation (D and Figure 11—source data 2) and fusion index
(E and Figure 11—source data 3) plotted relative to varying Sunitinib concentrations in 54.6 control (red) and 54.12 FSHD (blue) myoblasts. Statistical
analysis described in Figure 11—source data 1–3. All experiments were independently performed 3 times. Bar represents statistical test significance at
each concentration of Sunitinib, where an asterisk denotes p<0.01, while N.S. means non-significant. Scale bars equal 50 mm (A) 200 mm (B).
DOI: 10.7554/eLife.11405.021
The following source data is available for figure 11:
Source data 1. A linear model that describes the relationship between the shape (eccentricity) of control 54.6 and FSHD 54.12 human myoblasts relative
to different doses of Sunitinib.
DOI: 10.7554/eLife.11405.022
Source data 2. A binomial model that tests the relationship between the proliferation of control 54.6 and FSHD 54.12 human myoblasts with different
doses of Sunitinib.
DOI: 10.7554/eLife.11405.023
Source data 3. A binomial model that tests the relationship between the fusion of control 54.6 and FSHD 54.12 human myoblasts relative to different
doses of Sunitinib.
DOI: 10.7554/eLife.11405.024
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contrast, myoblasts containing the D4Z4 contraction are sensitive to Sunitinib, which alters cell mor-
phology to resemble control myoblasts. Importantly, these FSHD human myoblasts have an
increased proliferation rate and greater myogenic differentiation capacity when treated with
Sunitinib.
Sunitinib improves the regenerative capacity of FSHD myoblasts in vivo
We then tested whether Sunitinib could improve the regenerative capacity of human FSHD 54.12
myoblasts in vivo by grafting into regenerating muscles of immunodeficient, NOD/scid/g-chain
Figure 12. Sunitinib improves engraftment and differentiation of human FSHD myoblasts in murine skeletal muscle. (A) Representative 8 mm thick
cryosections from the tibialis anterior (TA) muscle of immunodeficient mice transplanted with 1  106 human 54.12 FSHD myoblasts per muscle, and
dosed with 20 mg/kg/day Sunitinib or PBS (control) for 3 weeks. Immunofluorescence for human-specific LAMIN A/C (green) and SPECTRIN (green)
reveal the location and fate of transplanted cells, murine Laminin (red) delimits all myofibres and Hoechst (blue) reveals total nuclei. (B) Quantification of
the total number of LAMIN A/C cells from each section per TA, subdivided into cells located in the interstitum (grey hatched) and nuclei (myonuclei)
within myofibres (black) (also see Figure 12—source data 1). (C) Quantification of the mean number of human SPECTRIN positive myofibres per TA
section (also see Figure 12—source data 2). (D) Quantification of the total number of human SPECTRIN positive myofibres containing at least one
human LAMIN A/C positive cell. (E) The mean number of SPECTRIN-positive myofibres per TA section along the length of the muscle. Data is
mean ± SEM from 4 control and 4 Sunitinib-treated mice, with statistical significance (p<0.05) tested against control mice using an unpaired Student’s t-
test and indicated with an asterisk. Further statistical analysis is described in Figure 12—source data 1 and 2. Scale bar represents 100 mm.
DOI: 10.7554/eLife.11405.025
The following source data is available for figure 12:
Source data 1. A binomial model evaluating whether the proportion of LAMIN A/C+ nuclei derived from grafted FSHD 54.12 human myoblasts in a
muscle fibre is significantly affected by exposure to Sunitinib.
DOI: 10.7554/eLife.11405.026
Source data 2. A binomial model evaluating whether the proportion of muscle fibres containing SPECTRIN and LAMIN A/C derived from grafted
FSHD 54.12 human myoblasts is significantly affected by exposure to Sunitinib.
DOI: 10.7554/eLife.11405.027
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knockout mice (Figure 12). Mice were pre-treated with an intraperitoneal injection of 20 mg/kg Suni-
tinib malate or PBS control for 24 hr prior to cryoinjury of the tibialis anterior (TA) muscle to induce
regeneration. TA muscles were then grafted intramuscularly with 1  106 54.12 FSHD myoblasts,
which had been cultured in control medium or pre-treated with 250 ng/ml Sunitinib for 24 hr. Mice
were given 20 mg/kg/day Sunitinib or PBS for 3 weeks.
Analysis was performed blinded. After 3 weeks, the TA muscles were removed and serial cryosec-
tions cut along the length of the muscle. Cryosections were immunostained with human-specific anti-
bodies against LAMIN A/C to quantify donor cell engraftment and SPECTRIN to measure myogenic
differentiation of donor myoblasts (Figure 12A). There was a significant increase in both the total
number of LAMIN A/C positive cells (total from all cryosections along the length of the muscle)
(Figure 12B, Figure 12—source data 1) and the number of LAMIN A/C positive cells located within
myofibres (myonuclei), in mice treated with Sunitinib compared to controls (Figure 12B). The mean
number of SPECTRIN positive myofibres per section (Figure 12C, Figure 12—source data 2) and
the total number of LAMIN A/C positive cells located within SPECTRIN-positive myofibres
(Figure 12D) were also increased significantly in mice treated with Sunitinib compared to controls.
Finally, increased engraftment in Sunitinib-treated samples was also seen along the length of the
muscle (Figure 12E). Taken together, this shows that Sunitinib treatment improves the regenerative
capacity of human FSHD myoblasts by increasing their engraftment and myogenic differentiation.
Discussion
We report that Ret is a novel mediator of muscle stem cell function, is regulated by DUX4 and con-
tributes to the pathogenic phenotype of FSHD. We focused on Ret signalling as a potential mediator
of DUX4-induced muscle pathology for several reasons. FSHD is characterised by the often asym-
metric wasting of facial, shoulder and upper arm muscles (Tawil, 2008), and can be associated with
several non-muscle tissue pathologies including sensorineural hearing loss and retinal vasculopathies
(Verhagen et al., 1995). Development of the auditory system, retinal patterning and facial muscles
have been shown to depend on Ret signalling in a number of species. Ret is expressed in the second
pharyngeal arch, from which some facial muscles arise, both in mouse and zebrafish (Knight et al.,
2011; Pachnis et al., 1993). Additionally, Ret, GFRa1 and GFRa2 are expressed in the retina and
the sensory epithelium of the cochlea, both of which can be affected in FSHD (Golden et al., 1999;
Zordan et al., 2006; Yu et al., 1998). Phenotypic analysis of Ret, GFRa (Enomoto et al., 1998;
Tomac et al., 2000; Rossi et al., 1999; Honma et al., 2002; Lindahl et al., 2000) and GFL
(Honma et al., 2002; Moore et al., 1996; Heuckeroth et al., 1999; Tomac et al., 2002)-mutant
mice have not reported a skeletal muscle phenotype, although this may have been overlooked due
to the severe phenotype and perinatal lethality of some mutant lines. However, Ret is expressed in
the indirect flight muscles of Drosophila, and overexpression of constitutively active Ret (RETMEN2B)
in muscle via a MEF2-GAL4 driver causes increased muscle fibre size, irregular myofibrils and abnor-
mal actin deposits (Klein et al., 2014). Interestingly, irregular myotube morphology is often reported
in FSHD patient-derived cultures (Barro et al., 2010; Tassin et al., 2012). As we found that Ret was
activated by DUX4 in murine satellite cells, it becomes a potential candidate for contributing to
DUX4-induced myopathy.
There has been no description of Ret function during myogenesis in mammals, despite
the descriptions of Ret pathway genes expressed in specific muscle cell populations, including facial
muscle precursors (Golden et al., 1999; Natarajan et al., 2002; Knight et al., 2011). We found that
Ret and three of its co-receptors: Gfra1, Gfra2 and Gfra4 are dynamically expressed in mammalian
limb satellite cells. Intriguingly, Ret expression was higher during proliferation, whereas Gfra1, Gfra2
and Gfra4 expression increased upon differentiation. This reciprocal expression pattern between Ret
and its co-receptors also occurs in other cell types (Li et al., 2009) and so may regulate Ret signal-
ling by feedback loops. Additionally, the ligands GDNF and PSPN, required to activate Gfra1 and
Gfra4 (and to a lesser extent Gfra2), are expressed by muscle fibres (Golden et al., 1999; Yang and
Nelson, 2004; Lindahl et al., 2000), suggesting that myofibres may signal to satellite cells via Ret
signalling. We also found that RET is expressed at low levels in primary human myoblasts, revealing
a conserved expression in vertebrate muscle. Constitutive-expression and knockdown studies
revealed that Ret signalling is required to maintain a proliferating myoblast population and prevent
premature cell cycle exit and myogenic differentiation. Specifically, constitutively active RET
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increased satellite cell proliferation but did not affect terminal differentiation. Consistent with this,
siRNA-mediated knockdown of Ret reduced Pax7 expression, concomitant with reduced satellite cell
proliferation, whilst increasing differentiation. Knockdown of Gfra1, Gfra2 or Gfra4 causes similar, if
less severe, defects suggesting that Ret is interacting with its Gfra co-receptors to control the switch
from proliferation to differentiation in myoblasts.
Having shown that Ret is involved in the control of myogenesis, we aimed to understand its role
in mediating DUX4 pathology. DUX4 is pathogenic in both myoblasts and differentiated muscle
(Vanderplanck et al., 2011; Bosnakovski et al., 2008a, 2014; Kowaljow et al., 2007;
Wallace et al., 2011; Dandapat et al., 2014). Recent microarray and ChIP-seq datasets reveal that
DUX4 causes wide-ranging transcriptional disruption in myogenic cells (Geng et al., 2012;
Banerji et al., 2015; Rahimov et al., 2012; Knopp et al., 2016) , with its potent transcriptional acti-
vation through its C-terminal domain (Geng et al., 2012; Clapp et al., 2007; Kawamura-
Saito et al., 2006). However, identifying which disrupted pathways directly contribute to DUX4-spe-
cific pathology is crucial when considering future drug design to treat FSHD.
Ret is genetically downstream of DUX4 in myoblasts, but does not appear to be a direct tran-
scriptional target. Transgenic analysis has shown that in mouse, 1.9 kb 5’ of the Transcriptional Start
Site (TSS) of Ret is sufficient to drive tissue specific expression (Zordan et al., 2006). However, analy-
sing two published ChIP-Seq datasets of DUX4 overexpression in human myoblasts (Geng et al.,
2012; Choi et al., 2016), we failed to identify significant peaks within 15 kb 5’ of the Ret TSS. In
addition, sequence analysis also failed to find a DUX4 consensus binding site (TAATCTAATCA –
[Zhang et al., 2016]) within this same 15 kb region. It is of note however, that the C-terminus of
DUX4 can recruit acetyltransferases (p300/CBP) to histones to induce acetylation, hence promoting
transcription at sites distant to DUX4 DNA binding (Choi et al., 2016), so DUX4 could still directly
controlling Ret in an epigenetic manner. However, also arguing against Ret being a direct transcrip-
tional target of DUX4 is our observation that Ret expression is not only enhanced by DUX4 and the
constitutively active tMALDUX4-VP16, but also by our DUX4 dominant-negative tMALDUX4-ERD
construct in the microarray analysis. The tMALDUX4-ERD construct contains the two DNA binding
homeodomains of DUX4, so should select the same cohort of transcriptional targets as DUX4. How-
ever, if DUX4 binds directly to the Ret promoter, tMALDUX4-ERD should suppress transcription and
so reduce Ret expression, but this is the opposite to what we observe. Together, these observations
indicate that DUX4 affects Ret expression indirectly, via binding to genes that, in turn, control Ret
expression.
Blocking Ret expression or signalling increases the probability of DUX4-expressing myoblasts to
differentiate into multinucleate myotubes. Despite this, some aspects of DUX4-mediated patholo-
gies were not rescued by Ret inhibition. For example, inhibition of Ret using Sunitinib did not alter
DUX4-induced apoptosis. DUX4 transcriptionally dysregulates a large number of pathways, so it is
unlikely that one pathway only is responsible for all pathological characteristics (Banerji et al.,
2015). For example, we have recently shown that b-catenin signalling is important for DUX4-medi-
ated transcriptional dysregulation in skeletal muscle (Banerji et al., 2015).
To investigate the relative importance of Ret in mediating DUX4 action, we adopted a pharmaco-
logical approach that allowed us to modify Ret signalling in a dose-dependent manner. As the read-
out, we used the suppression of differentiation caused by constitutive CA RET51 (RET51-MENA)
expression in murine C2C12 myoblasts and asked at which doses we could inhibit Ret to rescue dif-
ferentiation, without causing deleterious side-effects. Comparison of Ret inhibitors Zactima (Vande-
tanib/ZD6474) (Carlomagno et al., 2002), TG101209 (Pardanani et al., 2007) and Sunitinib (Sutent,
SU11248) (Kim et al., 2006) revealed that Suntinib showed the most robust rescue of CA RET51-
mediated inhibition of myogenesis. We further tested the ability of Sunitinib to rescue DUX4-medi-
ated phenotypes in murine satellite cells and showed that we could again rescue differentiation, but
not proliferation: consistent with the effects of siRNA-mediated knockdown of Ret. Zactima,
TG101209 and Sunitinib also inhibit other receptor tyrosine kinases, including VEGFR, EGF and MET
(Plaza-Menacho et al., 2014). Of note, Vegfr2 is also a DUX4 target identified in our microarray
screen (Banerji et al., 2015), highlighting another potential mediator of DUX4 pathology in myo-
blasts. Since many of these receptors activate the same intracellular pathways as Ret, it will be
important to understand their relative roles and redundancies, when activated in the context of
FSHD.
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Since DUX4 up-regulates Ret, and Sunitinib can clearly rescue the differentiation block caused by
CA-RET51 in C2C12 myoblasts, we investigated intracellular signalling events. ERK and AKT are two
key intracellular mediators of Ret signalling e.g. (Mograbi et al., 2001). ERK1/2 phosphorylation was
inhibited by Sunitinib in DUX4-expressing iC2C12-DUX4 myoblasts, but not in control myoblasts not
expressing DUX4, suggesting a potential mechanism by which DUX4-mediated Ret signalling could
inhibit differentiation. In contrast, AKT phosphorylation was unaltered by inducing DUX4. Although
Ret can operate through ERK1/2 signalling, it is possible that Sunitinib could also be acting on
ERK1/2 phosphorylation activated by other pathways perturbed by, or in response to, DUX4.
To assess whether Sunitinib could be used to ameliorate FSHD pathologies in man, we used
human myoblast lines isolated from a mosaic FSHD1 patient (Krom et al., 2012). We assessed
whether Sunitinib could rescue cell morphology, proliferation and the differentiation capacity of
human myoblasts displaying FSHD pathologies. Using statistical models we showed that Sunitinib
could induce the FSHD myoblasts to adopt the phenotype of isogenic myoblasts lacking the D4Z4
contraction. Transplantation assays of FSHD myoblasts into cryodamaged immunodeficient mice
showed increased engraftment of FSHD myoblasts occurred in response to daily systemic Sunitinib
treatment. Therefore, this pre-clinical model for evaluating modifiers of FSHD pathology identifies
Sunitinib as a potential therapeutic agent for FSHD.
In conclusion, we have shown that Ret is a novel regulator of satellite cell function in mammalian
muscle, and contributes to the FSHD phenotype. Specifically, blocking DUX4-mediated Ret signal-
ling increases myogenic differentiation, giving further insight into the molecular pathology of DUX4
and highlighting Ret signalling as potential drug target. Crucially, the clinically-approved RET inhibi-
tor Sunitinib (Widmer et al., 2014) rescues cell morphology, proliferation and myogenic differentia-
tion in human FSHD myoblasts both in vitro and in vivo. Given that FSHD is currently incurable, our
findings highlight RTK inhibitors as a potential novel therapeutic strategy to treat muscle wasting in
FSHD.
Materials and methods
Animals
Experimental procedures were performed in accordance with British law under the provisions of the
Animals (Scientific Procedures) Act 1986, as approved by the King’s College London and University
College London Ethical Review Process committees. C57BL/10 male mice aged between 8 and 10
weeks were used for myofibre and satellite cell-derived myoblast preparations. Immunodeficient
NOD/scid/g-chain mice were used for grafting experiments, performed under UK Home Office Proj-
ect Licence 70/8566. All surgery was performed under isoflurane anesthesia, and every effort made
to minimize pain and suffering, including use of analgesics.
Cell culture and primary satellite cell preparation
Single myofibres were isolated from the extensor digitorum longus (EDL) as previously described
(Moyle and Zammit, 2014). Briefly, dissected EDLs were digested in DMEM (+Glutamax) (Thermo
Fisher Scientific, Waltham, MA) containing 0.2% collagenase (Sigma-Aldrich, Dorset, UK) for 2 hr in a
37˚C 5% CO2 incubator before manual disruption with a heat-polished glass pipette in 5% bovine
serum albumin (BSA) (Sigma Aldrich) coated dishes. Individual washed myofibres with associated
quiescent satellite cells were subsequently fixed in 4% paraformaldehyde/PBS (PFA) or cultured in
non-adherent or adherent conditions. Non-adherent cultures were grown in DMEM-Glutamax
(Thermo Fisher Scientific) supplemented with 10% horse serum (HS) (Thermo Fisher Scientific), 0.5%
chicken embryo extract (CEE) and 1% Penicillin-Streptomycin (Sigma Aldrich) for up to 72 hr. For
adherent cultures of proliferating satellite cells, myofibres were plated on 1 mg/ml Matrigel (Collab-
orative Research Inc., Bedford, MA) coated dishes in DMEM (Glutamax) supplemented with 20% foe-
tal calf serum (FBS)-Gold (Thermo Fisher Scientific), 10% HS, 1% CEE, 10 ng/ml basic FGF
(Peprotech, Rocky hill, NJ) and 1% Penicillin-Streptomycin for 72 hr. Subsequently, myofibres were
removed by pipette agitation and satellite cells re-plated after trypsinisation in 0.25% Trypsin-EDTA.
Primary human myoblasts were obtained from biopsies of the vastus lateralis of consenting indi-
viduals (approved by the UK National Health Service Ethics Committee (London Research Ethics
Committee; reference 10/H0718/10 and in accordance with the Human Tissue Act and Declaration
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of Helsinki). Biopsies were digested in basal medium (PromoCell containing collagenase B and dis-
pase II) and single cells isolated via 100 mM cell strainer as previously described (Agley et al., 2015).
Adherent cells were cultured for 7 days in skeletal muscle cell growth medium
(PromoCell, Heidelberg, Germany) and the NCAM/CD56+ myogenic population collected via mag-
netic activated cell sorting (MACS).
The immortalised human myoblast lines 54.6 (un-contracted D4Z4, no DUX4 expression) and
54.12 (contracted D4Z4, DUX4 expression) from a mosaic patient were a kind gift from V. Mouly and
Silvere van der Maarel (Krom et al., 2012) and were verified by assessing DUX4 expression and
tested for mycoplasma. Both lines were maintained in skeletal muscle cell growth medium (Promo-
Cell, C-23160) and differentiated in skeletal muscle cell differentiation medium (PromoCell supple-
mented with 50 mg/ml Gentacmycin).
C2C12 myoblasts (Yaffe and Saxel, 1977), iC2C12-DUX4 and iC2C12-DUX4c myoblasts
(Bosnakovski et al., 2008a) and HEK 293T cells were maintained in DMEM supplemented with 10%
FBS, 1% L-Glutamine (Sigma Aldrich) and 1% Penicillin-Streptomycin. For differentiation, both satel-
lite cell-derived myoblasts and C2C12 myoblasts were cultured in mitogen-poor medium, containing
DMEM, 2% HS, 1% Penicillin-Streptomycin and 1% L-Glutamine. iC2C12-DUX4 and iC2C12-DUX4c
myoblasts were tested for DUX4 and DUX4c induction respectively.
Retroviral expression constructs
Plasmids were obtained encoding human RET9 and RET51 and constitutively active (CA) forms con-
taining the Cys634Lys mutation that occurs in multiple endocrine neoplasia type 2A (MEN2A)
patients (de Graaff et al., 2001). Coding sequences were sub-cloned into a modified pMSCV-puro
vector (Takara Bio Europe, Saint-Germain-en-Laye, France), in which the puromycin resistance gene
was replaced with an internal ribosomal entry site (IRES) and enhanced green fluorescent protein
(eGFP), allowing transduced cells to be identified due to the presence of eGFP (Zammit et al.,
2006). The DUX4 and DUX4c constructs have previously been published (Banerji et al., 2015). All
constructs were sequenced to ensure fidelity.
Retroviruses were produced using HEK 293T packaging cells, by co-transfecting the expression
vectors in the presence of an ectopic helper plasmid. Replication incompetent viral particles were
harvested from the culture medium and expression confirmed by western blot and
immunofluorescence.
Retroviral transduction
C2C12 myoblasts and satellite cell-derived myoblasts were plated at 70% confluency and transduced
with control, RET, RET mutants, DUX4c or DUX4-encoding retroviruses in the presence of 4 mg/ml
Polybrene for 6 hr at 37˚C, 5% CO2 in proliferation medium, before the medium was replaced.
siRNA-mediated gene knockdown
Satellite cells were transfected with 20 nM of control or Ret Silencer Select siRNA (Thermo Fisher
Scientific) in the presence of Lipofectamine RNAiMAX (Thermo Fisher Scientific) for 6 hr at 37˚C, 5%
CO2 in proliferation medium. The siRNA sequence 5’-GCUUGUACAUCGGGACUUATT-3’ (ID:
s72895) was used to knockdown murine Ret expression, and control siRNA was supplied by Thermo
Fisher Scientific. Gene knockdown was confirmed 48 hr after transfection.
Ret signalling inhibition using clinically approved drugs
Three small molecule tyrosine kinase inhibitors were analysed for their ability to inhibit RET signal-
ling. All drugs are ATP-competitive inhibitors of tyrosine kinases, and were obtained from Selleck-
chem.com: Sunitinib (Sutent, SU11248) (Kim et al., 2006), TG101209 (Pardanani et al., 2007) and
Zactima (Carlomagno et al., 2002). The chemical structures of each compound can be found in
(Pardanani et al., 2007; Kim et al., 2006; Wedge et al., 2002).
Quantitative RT-PCR
Cells were cultured in 6-well plates for at least 48 hr under experimental conditions and total RNA
extracted using RNeasy Kit (QIAGEN Ltd, Manchester, UK ). Between 500 ng – 1 mg of RNA was
used to prepare cDNA using the QuantiTect Reverse Transcription Kit with genomic DNA wipeout
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(QIAGEN). RT-qPCR was performed on an Mx3005PQPCR system (Agilent Technologies LDA UK
Ltd, Stockport, UK) with MESA Blue qPCR MasterMix Plus and ROX reference dye (Eurogentec Ltd,
Southampton, UK). Primers used were as follows:
Total Ret (F: 5’-AAGCAGGAGCCAGACAAGAG-3’ and R: 5’-ACACCTTCGGACTCACTGCT-3’),
Ret9 (F: 5’-GATCCAGAGGCCAGACAAC -3’ and R: 5’- GTAGAATCTAGTAAATGCA-3’),
Ret51 (F: 5’-GATCCAGAGGCCAGACAAC-3’ and R: 5’-AGGACTCTCTCCAGGCCAG-3’),
GFRa1 (F: 5’-GCACAGCTACGGGATGCTC-3’ and R: 5’-CTCTGGCTGGCAGTTGGT-3’),
GFRa2 (F: 5’-ACCGTGTGCCCAGCGAGTATA-3’ and R: 5’-CGACAGTTGGCGTGGAAGT-3’),
GFRa3 (F: 5’- GGAAAATGAATCTTAGCAAGTTGAA-3’ and R: 5’- TTGTCGTGAAGAGTACACAGCA
TAG-3’),
GFRa4 (F: 5’-ACCCCTGCTTGGATGGTGCC-3’ and R: 5’-CAGCCAGGACACCTTGGGCG-3’),
Gapdh (F: 5’-GTGAAGGTCGGTGTGAACG-3’ and R: 5’-ATTTGATGTTAGTGGGGTCTCG-3’)
Tbp (F: 5’-ATCCCAAGCGATTTGCTG-3’ and R: 5’-CCTGTGCACACCATTTTTCC-3’)
Primers for murine Pax7, MyoD and Myf5 have previously been published (Collins et al., 2009).
Human primers were as follows:
RPLPO (F: 5’- TCTACAACCCTGAAGTGCTTGAT-3’ and R: 5’- CAATCTGCAGACAGACACTGG-
3’)
Cyclin D1 (F: 5’-GCCGAGAAGCTGTGCATC -3’ and R: 5’-CCACTTGAGCTTGTTCACCA-3’),
MYOD (F: 5’- GCTCCGACGGCATGATGG -3’ and R: 5’- GACACCGCCGCACTCTTCCC -3’),
MYOG (F: 5’- CCAGGGGTGCCCAGCGAATG -3’ and R: 5’- AGCCGTGAGCAGATGATCC -3’),
MyHC (F: 5’- AGCAGGAGGAGTACAAGAAG -3’ and R: 5’- CTTTGACCACCTTGGGCTTC -3’) and
RET (F: 5’-GCTCCACTTCAACGTGTC-3’ and R: 5’-GCAGCTTGTACTGGACGTT-3’).
Murine samples were normalised to the housekeeping genes Gapdh and/or Tbp (as designated)
and human samples normalised to RPLPO.
Immunolabelling
Floating myofibres or plated satellite cells were fixed in 4% paraformaldehyde/PBS, permeabilised
with 0.5% Triton/PBS (Sigma Aldrich) and blocked in PBS containing 5% swine serum + 5% goat
serum (DakoCytomation, Glostrup, Denmark) for 1 hr (except for samples using goat RET51 anti-
body, which were blocked in 10% swine serum). Samples were incubated in primary antibody over-
night at 4˚C, washed 3 times in 0.025% Tween/PBS and visualised by incubating with AlexaFluor
conjugated secondary antibodies (Thermo Fisher Scientific) at 1/500 dilution for 1 hr at room tem-
perature. Nuclei were visualised by mounting in aqueous mountant containing DAPI (Vectashield),
for further detail see (Moyle and Zammit, 2014). Primary antibodies used were: goat anti-RET (C-
20, Santa Cruz Biotechnology, Dallas TX, 1/150), rabbit anti-RET51 (C-19, Santa Cruz Biotechnology,
1/150) and rabbit anti-pRET (Tyr1062-R, Santa Cruz Biotechnology, 1/150), mouse anti-Pax7 (Devel-
opmental Studies Hybridoma Bank, Iowa City, IA, 1/10), mouse anti-Myogenin (F5D, Developmental
Studies Hybridoma Bank, 1/10) and mouse anti-MyHC (MF-20, Developmental Studies Hybridoma
Bank, 1/300), rabbit anti-eGFP (A11122, Thermo Fisher Scientific, 1/500), chicken anti-eGFP
(ab13970, Abcam, Cambridge, UK, 1/1000), rabbit anti-phospho-Histone H1 (06–597 Thermo Fisher
Scientific, 1/300), rabbit anti-phospho-Histone H3 (06–570, Thermo Fisher Scientific, 1/100), rabbit
anti-Desmin (D93F5, Cell Signalling Technology, Danvers, MA, 1/250), rabbit anti-Ki67 (SP6, A.
Menarini Diagnostics Ltd, Winnersh, UK, 1/200) and mouse anti-tubulin (E7-C, Developmental Stud-
ies Hybridoma Bank, 1/1000).
EdU analysis was performed with the Click-iT EdU Alexa Fluor Imaging Kit, by incubating cells for
2 hr with 10 mM of 5-Ethynyl-2’-deoxyuridine (EdU) before fixation and processing as per manufac-
turer’s instructions (Thermo Fisher Scientific).
Immunoblot analysis
HEK 293T cells were transfected with RET expression vectors for 24 hr and total protein extracted in
the presence of a complete protease inhibitor cocktail (PIC, Roche Diagnostics Ltd, Burgess Hill,
UK). Samples were quantified using the DC Protein Assay (Biorad Laboratories, Hercules, CA, 500–
0116) and equal quantifies run on pre-cast 4–20% electrophoresis gels (Thermo Fisher Scientific)
with 0.35 ml dithiothreitol and bromophenol blue dye at 120 V. Gels were transferred to PVDF mem-
branes using the iBlot dry-blotting system (Thermo Fisher Scientific), blocked in 5% non-fat milk
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powder/PBS (Marvel: Premier Foods, St Albans, UK) and incubated overnight at 4˚C in primary anti-
body dissolved in 1% milk powder/PBS.
iC2C12-DUX4 myoblasts (Bosnakovski et al., 2008a) were plated at 3000 cells/cm2 and DUX4
expression induced by the addition of 500 ng/ml doxycycline hyclate (Thermo Fisher Scientific,
J60579) with/without 250 ng/ml Sunitinib for 20 hr. Myoblasts were lysed in RIPA buffer (CST,
9806S) and subjected to three freeze/thaw cycles and the lysate incubated on ice for 20 min and
then centrifuged for 20 min at 4˚C. Protein concentration was quantified using the DC Protein Assay
(Biorad, 500–0116), and 40 mg protein was mixed with 5x Laemmli Buffer, subjected to 10% SDS-
PAGE and transferred onto a nitrocellulose membrane (Sigma-Aldrich, WHA10402578). Membranes
were blocked in 5% non-fat milk powder in TBS/0.1% Tween 20 (TBS/T) (Sigma-Aldrich, P5927) and
incubated with primary antibodies overnight at 4˚C. Primary antibodies used were goat anti-RET
(C20, Santa Cruz Biotechnology, 1/150), rabbit anti-RET51 (C-19, Santa Cruz Biotechnology, 1/150),
rabbit anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (9101, Cell Signalling Technology, 1/
1000), rabbit anti-total p44/42 MAPK (Erk1/2) (137F5, Cell Signalling Technology, 1/1000), rabbit
anti-phospho-Akt (Ser473) (D9E, Cell Signalling Technology 1/2000), mouse anti-total AKT (40D4,
Cell Signalling Technology, 1:2000), mouse anti-DUX4 (9A12, Merck Millipore, 1/1000) and rabbit
anti-Caveolin-1 (sc-894, Santa Cruz Biotechnology, 1:500).
Membranes were then washed and protein bands visualised by incubating with horseradish per-
oxidase (HRP)-conjugated secondary antibodies (GE Healthcare, Chalfont St Giles, UK, Na934V,
NA931V, 1/5000) for 1 hr at room temperature. Membrane bound protein was visualised using clar-
ity western ECL substrate (BioRad, 170–5061), and band intensity was quantified with ChemiDoc MP
System (BioRad). For iC2C12-DUX4 myoblasts, band intensities were normalised to housekeeping
protein Caveolin-1. The ratios of pERK:tERK and pAKT:tAKT in the treated groups were subse-
quently compared to the ratios in the control group.
Apoptosis assay and FACs
iC2C12-DUX4 myoblasts were induced to express DUX4 with 250 ng/ml or 500 ng/ml doxycycline
for 24 hr in the presence of 0, 250 ng/ml or 500 ng/ml Sunitinib malate. Samples were trypsinised
and stained with APC-conjugated Annexin V Apoptosis detection kit, according to manufacturer’s
instructions (BD Biosciences, Franklin Lakes, NJ). Samples were run on a CyAn ADP flow cytometer
(Beckman Coulter) and analysed using FlowJo software.
Human myoblast transplantation
Human cell work in the Tedesco laboratory has been conducted under the approval of the National
Health Service Health Research Authority Research Ethics Committee, reference no. 13/LO/1826;
IRAS project ID no. 141100. Transplants were performed under UK Home Office Project Licence 70/
8566. Immortalised human FSHD clone 54.12 myoblasts were cultured at low density in skeletal mus-
cle cell growth medium (Promocell, C-23160) and separate cohorts either pre-treated 24 hr before
transplantation with 250 ng/ml Sunitinib malate or control medium. NOD/scid/g-chain knockout
immunodeficient mice were given an intraperitoneal injection of 20 mg/kg/day Sunitinib malate dis-
solved in Ca2+/Mg2+-free PBS (n = 4), while non pre-treated controls received PBS (n = 4). 24 hr
later, TA muscles of all eight NOD/scid/g-chain knockout immunodeficient mice were cryoinjured
with a metal probe pre-cooled in liquid nitrogen for 30 s to induce regeneration. TA muscles of the
four mice pre-treated with Sunitinib were then injected using a 30G syringe (BD Biosciences) with
1  106 54.12 FSHD myoblasts that had been pre-treated with Sunitinib in vitro, while 1  106 non-
treated 54.12 FSHD myoblasts per mouse were injected into PBS-treated mice (n = 4) (Gerli et al.,
2014). Mice grafted with myoblasts pre-treated with Sunitinib then received daily intraperitoneal
injections of 20 mg/kg/day Sunitinib malate dissolved in Ca2+/Mg2+-free PBS, while non pre-treated
controls received PBS. Three weeks after transplantation, mice were humanely killed and grafted TA
muscles removed and frozen in isopentane cooled in liquid nitrogen. Muscles were mounted using
gum tragacanth on cork and serial transverse sections were cut at 8 mm using a Leica CM 1850 UV
cryostat (Leica Biosystems, Milton Keynes, UK).
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Analysis of cell engraftment
Cryosections 8 mm thick and spaced 112 mm along the length of the muscle were collected for analy-
sis with human-specific antibodies to measure engraftment of donor myoblasts. Frozen sections
were fixed in 4% PFA for 10 min, permeabilised with 0.1% Triton X100/1% BSA (Sigma Aldrich)/PBS
and blocked in 10% donkey serum (Dakocytomation) in 0.1% Triton X100/1% BSA/PBS. Cryosections
were then incubated with mouse anti-human LAMIN A/C (NCL-LAM, Leica Biosystems) and mouse
anti-human SPECTRIN (NCL-SPEC1, Leica Biosystems) to locate engrafted cells and myofibres,
together with rabbit anti-mouse Laminin (L9393, Sigma Aldrich) to immunostain extracellular matrix
and delimit myofibres. Samples were counterstained with Hoechst to identify total nuclei. The total
number of donor-derived LAMIN A/C-positive nuclei within or outside of myofibres, and donor-
derived SPECTRIN-positive myofibres were counted in each section along the grafted TA and
expressed either as a total per mouse (all sections combined) or an average per section. Quantifica-
tion was performed blinded with the experimenter unaware of whether the cells were from Suniti-
nib-treated or control mice.
Statistics
Data was analysed using either two-tailed Student’s t-tests, or by statistical models fitted to the data
that incorporated random effects due to mouse or between experiment variations (as determined in
text). Quasi-Poisson models were used for evaluating the significance of differences in the numbers
of cells between conditions and mixed binomial models employed likewise for ratios including the
fusion index. Models tested either the linear relationship between a factor and the result, or each
combination of factors as an independent parameter. The fusion index was expressed as the ratio of
the number of nuclei incorporated into MyHC+ fibres divided by the total number of nuclei in the
field of view. Statistical models and analyses were generated using the R programming language
(R Core Team, 2011) and Excel.
Image analysis
Cell eccentricity analysis was performed on Tubulin immunolabelled cells using a customised R
script, written using the EBImage package (Pau et al., 2010) . Images were first pre-processed using
a low pass filter to remove low intensity background staining and a high pass filter to exclude non-
specific high intensity background based on size and morphology. Cells with overlapping cytoplasm
were segregated into independent objects prior to quantification using Voroni segmentation in
which DAPI nuclear staining was used as an anchor to define cells; annotated images of segregation
were output for visual assessment of correct segregation. The eccentricities of each cell cytoplasm
(defined by Tubulin immunolabelling in pre-processed, segregated images) was then computed for
each image and the average eccentricity of the frame was obtained, eccentricity computes the cell
shape deviation from a circle (1) to a line (0) (Source Code file-Measuring Cell Eccentricity.r).
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